BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Wolfe Laboratories Inc. Presents Antibody-Drug Conjugate Characterization Research at National Meeting of the American Chemical Society


4/8/2013 12:34:43 PM

WATERTOWN, MASS., April 8, 2013. Wolfe Laboratories today announced the presentation of an abstract related to its research efforts surrounding antibody-drug conjugates (ADCs) at the 245th National Meeting of the American Chemical Society, held April 7-11 in New Orleans. The abstract details how scientists at Wolfe Laboratories, along with their University of Kansas collaborators, have found that conjugation site heterogeneity in ADCs affects the overall surface charge, which can lead to variable and unpredictable pharmaceutical performance.

Janet Wolfe, President of Wolfe Laboratories, said, “ADCs are a rapidly growing class of oncology therapeutics that are incredibly promising, yet complex. Given the complexity of ADCs, the ability to control and fully characterize the conjugation sites will enable streamlined and cost-effective ADC discovery and development and may positively affect a conjugate’s development potential and commercial value. Wolfe is expanding its research efforts in this important area to better predict and control the pharmaceutical properties of ADCs. This type of research exemplifies our commitment to providing translational drug development solutions and actionable, meaningful information to our customers.”

The physiochemical stability of ADCs during manufacturing, storage and administration is an important factor influencing their therapeutic efficacy; however, it has remained unclear how covalent modifications alter the stability of these conjugates. Wolfe Laboratories researchers utilized analytical methods such as size-exclusion chromatography, dynamic light scattering and ion exchange chromatography to characterize the size and charge of conjugates created through conjugating fluorophores to lysine residues in the constant (Fc) region of IgG1. This research offers new understanding related to the effects of chemical conjugation on the stability of ADCs, providing important information on the effects of drug-to-antibody ratio and fluorophore hydrophobicity on the stability of Fc-conjugates.

The abstract titled, “The influence of payload on the physiochemical stability of Fc-conjugates,” was presented on April 7, 2013 and authored by: Nicholas Boylan, Robert J. Proos, Janet Wolfe and Jennifer S. Laurence.

About Wolfe Laboratories

Wolfe Laboratories delivers the highest quality translational drug development services for a global base of pharmaceutical and biotechnology clients. Our diverse scientific teams provide leading-edge, integrated solutions to advance breakthrough medicines.

To learn more about how Wolfe Laboratories can accelerate and increase the value of your drug candidates, visit us at www.wolfelabs.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES